Accepted: 4 June 2020
First Online: 7 July 2020
: C.R. has acted as a consultant of Amgen, Biothera, BMS, MSD, Novartis, Pierre Fabre, Roche, Sanofi and Ultimovacs. A.M. has acted as a consultant of Bayer, BPI, Daichii Sankyo, EISAI, Faron, Genticel, Imaxio, Molecular partners, Onxeo, Pierre Fabre, Pilar partners, Rigontec, Roche and Sanofi/BioNTech. K.F. has served on the advisory boards of AAA, Amgen, Astellas, AstraZeneca, Bayer, Clovis, Curevac, ESSA, Genentech, Janssen, MSD, Orion and Sanofi. C.C. has acted as a consultant of AstraZeneca, BMS, MSD, and Roche. B.B. has conducted research funded by Abbvie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, BMS, Celgene, Eli Lilly, GSK, Ignyta, Ipsen, Merck, MSD, Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, Spectrum Pharmaceuticals, Takeda and Tiziana Pharm. H.H. and P.R. declare no competing interests.